References
[1] Lazarus JV, Ekstedt M, Marchesini G, et al. A cross-sectional
study of the public health response to non-alcoholic fatty liver disease
in Europe. J Hepatol 2020, 72(1):14-24.
[2] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology
of nonalcoholic fatty liver disease-Meta-analytic assessment of
prevalence, incidence, and outcomes. Hepatology 2016, 64(1):73-84.
[3] Sanyal AJ. Past, present and future perspectives in nonalcoholic
fatty liver disease. Nature reviews Gastroenterology & hepatology 2019,
16(6):377-386.
[4] Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver
disease. Nat Rev Dis Primers 2015, 1:15080.
[5] Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis
in NAFLD - revisited after a decade. Hepatology 2020.
[6] Cai J, Zhang XJ, Li H. Role of innate immune signaling in
non-alcoholic fatty liver disease. Trends Endocrinol Metab 2018,
29(10):712-722.
[7] Tilg H, Burcelin R, Tremaroli V. Liver tissue microbiome in
NAFLD: next step in understanding the gut-liver axis? Gut 2020,
69(8):1373-1374.
[8] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in
liver disease: Pathophysiological basis for therapy. J Hepatol 2020,
72(3):558-577.
[9] Canfora EE, Meex RCR, Venema K, et al. Gut microbial metabolites
in obesity, NAFLD and T2DM. Nat Rev Endocrinol 2019, 15(5):261-273.
[10] Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota
and human NAFLD: disentangling microbial signatures from metabolic
disorders. Nature reviews Gastroenterology & hepatology 2020,
17(5):279-297.
[11] Chen M, Hui S, Lang H, et al. SIRT3 deficiency promotes
high-fat diet-induced nonalcoholic fatty liver disease in correlation
with impaired intestinal permeability through gut microbial dysbiosis.
Mol Nutr Food Res 2019, 63(4):e1800612.
[12] Giorgio V, Miele L, Principessa L, et al. Intestinal
permeability is increased in children with non-alcoholic fatty liver
disease, and correlates with liver disease severity. Digestive and liver
disease : official journal of the Italian Society of Gastroenterology
and the Italian Association for the Study of the Liver 2014,
46(6):556-560.
[13] Luther J, Garber JJ, Khalili H, et al. Hepatic injury in
nonalcoholic steatohepatitis contributes to altered intestinal
permeability. Cell Mol Gastroenterol Hepatol 2015, 1(2):222-232.
[14] Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut
vascular barrier disruption is a prerequisite for non-alcoholic
steatohepatitis development. J Hepatol 2019, 71(6):1216-1228.
[15] Miele L, Valenza V, La Torre G, et al. Increased intestinal
permeability and tight junction alterations in nonalcoholic fatty liver
disease. Hepatology 2009, 49(6):1877-1887.
[16] Zhou D, Pan Q, Shen F, et al. Total fecal microbiota
transplantation alleviates high-fat diet-induced steatohepatitis in mice
via beneficial regulation of gut microbiota. Sci Rep 2017, 7(1):1529.
[17] Zhao Z, Chen L, Zhao Y, et al. Lactobacillus plantarum NA136
ameliorates nonalcoholic fatty liver disease by modulating gut
microbiota, improving intestinal barrier integrity, and attenuating
inflammation. Appl Microbiol Biotechnol 2020, 104(12):5273-5282.
[18] De Munck TJI, Xu P, Verwijs HJA, et
al. Intestinal permeability in human
nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Liver Int 2020, 40(12):2906-2916.
[19] Xu R, Tan C, He Y, et al. Dysbiosis of gut microbiota and
short-chain fatty acids in encephalitis: a Chinese pilot study. Front
Immunol 2020, 11:1994.
[20] Verbeke KA, Boobis AR, Chiodini A, et al. Towards microbial
fermentation metabolites as markers for health benefits of prebiotics.
Nutr Res Rev 2015, 28(1):42-66.
[21] National Workshop on Fatty L, Alcoholic Liver Disease CSoHCMA,
Fatty Liver Expert Committee CMDA. Guidelines of prevention and
treatment for nonalcoholic fatty liver disease: a 2018 update. Zhonghua
Gan Zang Bing Za Zhi 2018, 26(3):195-203.
[22] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model
assessment: insulin resistance and beta-cell function from fasting
plasma glucose and insulin concentrations in man. Diabetologia 1985,
28(7):412-419.
[23] Ling Z, Liu X, Guo S, et al. Role of probiotics in mycoplasma
pneumoniae pneumonia in children: a short-term pilot project. Front
Microbiol 2018, 9:3261.
[24] Liu X, Cheng Y, Shao L, et al. Alterations of the predominant
fecal microbiota and disruption of the gut mucosal barrier in patients
with early-stage colorectal cancer. Biomed Res Int 2020, 2020:2948282.
[25] Hendy OM, Elsabaawy MM, Aref MM, et al. Evaluation of
circulating zonulin as a potential marker in the pathogenesis of
nonalcoholic fatty liver disease. APMIS 2017, 125(7):607-613.
[26] Gabele E, Dostert K, Hofmann C, et al. DSS induced colitis
increases portal LPS levels and enhances hepatic inflammation and
fibrogenesis in experimental NASH. J Hepatol 2011, 55(6):1391-1399.
[27] Di Ciaula A, Baj J, Garruti G, et al. Liver Steatosis,
Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending
Bidirectional Cross-Talk. J Clin Med 2020, 9(8):2648.
[28] Svegliati-Baroni G, Patricio B, Lioci G, et al.
Gut-pancreas-liver axis as a target for treatment of NAFLD/NASH. Int J
Mol Sci 2020, 21(16):5820.
[29] Verdam FJ, Rensen SS, Driessen A, et al. Novel evidence for
chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J
Clin Gastroenterol 2011, 45(2):149-152.